Item 8.01 Other Events.
As previously reported in its Quarterly Report on Form 10-Q for the quarterly
period ended September 30, 2022, Gamida Cell Ltd. (the "Company") was previously
engaged in discussions with Lonza Netherlands B.V. ("Lonza") to terminate that
certain Manufacturing Services Agreement, dated as of June 10, 2019 (the
"Manufacturing Agreement"), with Lonza for the manufacture of omidubicel.
On December 29, 2022, the Company entered into a settlement agreement (the
"Settlement Agreement") with Lonza pursuant to which the Company agreed to pay
an aggregate amount of €8,000,000 to Lonza in a series of installments, with the
first installment of €1,500,000 paid prior to December 31, 2022 and the final
installment payment to be paid no later than September 30, 2024. In connection
with these payments, Lonza and the Company agreed to terminate the Manufacturing
Agreement and to a mutual release of any claims arising out of the Manufacturing
Agreement.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
1
© Edgar Online, source Glimpses